4D Molecular Therapeutics, Inc. Common Stock

$9.195
USD
Last updated on --.
24h volume261.63K
24h highest9.3750 USD
24h lowest8.6170 USD
24h Price movement+4.08%

FDMT recent prices

24 Hours
+4.08%+$0.36
30 days
-16.36%-$1.710
60 days
-12.95%-$1.300
90 days
+4.92%+$0.41

Key data

Previous close8.8350 USD
Market cap451.67M USD
Volume261.63K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-3.0800 USD
Net income (FY)-160.90M USD
Revenue (FY)88.24M USD
Last report dateMay 7, 2026

About 4D Molecular Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersEMERYVILLE
Employees (FY)196.00
Revenue per employee (FY)450.21K USD
Net income per employee (FY)-820.90K USD
Listed onNasdaq
Official website

FDMT conversion tables

FDMTFDMT
USDUSD
0.5 FDMT4.597 USD
1 FDMT9.195 USD
5 FDMT45.97 USD
10 FDMT91.95 USD
USDUSD
FDMTFDMT
0.5 USD0.054377 FDMT
1 USD0.10875 FDMT
5 USD0.54377 FDMT
10 USD1.087 FDMT

FAQ

FDMT is trading at $9.195, +4.08% over the last 24 hours. Track live moves on the price chart at the top of this page.
The FDMT stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. FDMT is currently trading at $9.195, +4.08% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on FDMT price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. FDMT's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from FDMT; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against FDMT's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
4D Molecular Therapeutics, Inc. Common Stock's market cap is currently 451.67M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume261.63K
24h highest9.3750 USD
24h lowest8.6170 USD
24h Price movement+4.08%
FDMTFDMT
USDUSD
Start trade with FDMT Perpetual